Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFQ056 and Language Intervention in Young Children with Fragile X Syndrome
NCT02920892Phase 2Completed
- Start
- Aug 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mavoglurant in Fragile X syndrome (FXS) (3 arms). Primary endpoint: Change in Weighted Child Intentional Communication Score at Month 8. Started Aug 2017; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT02920892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920892.